Serotonin system implication in L-DOPA-induced dyskinesia: From animal models to clinical investigations

Frontiers in Neurology

Volumn 5 MAY, Issue , 2014, Pages

  Carta, Manolo ^a   Tronci, Elisabetta ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

5 HT1 receptor; Dopamine; Dyskinesia; L DOPA; Parkinson's disease; Serotonin

Indexed keywords

BUSPIRONE; DOPAMINE; DOPAMINE RECEPTOR; ELTOPRAZINE; LEVODOPA; SARIZOTAN; SEROTONIN UPTAKE INHIBITOR;

CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE MODEL; DOPAMINE BRAIN LEVEL; DRUG APPROVAL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DYSKINESIA; FEEDBACK SYSTEM; HUMAN; LEVODOPA INDUCED DYSKINESIA; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; REVIEW; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SYNAPTIC TRANSMISSION;

EID: 84904419329     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2014.00078     Document Type: Review

References (39)

1. Carta M, Bezard E. Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia. Neuroscience (2011) 198:245-51. doi: 10.1016/j.neuroscience.2011.07.070 2.
2. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Serotonin-dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias. Prog Brain Res (2008) 172:465-78. doi:10.1016/S0079-6123(08)00922-9
3. Tronci E, Carta M. 5-HT1 receptor agonists for the treatment of l-DOPA-induced dyskinesia: from animal models to clinical investigation. Basal Ganglia (2013) 3:9-13. doi:10.1093/brain/awn235
4. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, et al. Development of dyskinesias in a 5-year trial of ropinirole and l-dopa. Mov Disord (2006) 21(11):1844-50. doi:10.1002/mds.20988
5. de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 127(Pt 12):2747-54. doi:10.1093/brain/awh290
6. Ulusoy A, Sahin G, Kirik D. Presynaptic dopaminergic compartment determines the susceptibility to l-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci U S A (2010) 107(29):13159-64. doi:10.1073/pnas.1003432107
7. Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D. Serotonin neuron transplants exacerbate l-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci (2007) 27(30):8011-22. doi:10.1523/JNEUROSCI.2079-07.2007
8. Shin E, Garcia J, Winkler C, Bjorklund A, Carta M. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease. Neurobiol Dis (2012) 47(3):393-406. doi:10.1016/j.nbd.2012.03.038
9. Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA. l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem (2010) 112(6):1465-76. doi:10.1111/j.1471-4159.2009.06556.x
10. Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis (2006) 22(3):586-98. doi:10.1016/j.nbd.2006.01.009
11. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa? Mov Disord (2007) 22(1):1-9. doi:10.1002/mds.21060
12. Antonini A, Odin P, Opiano L, Tomantschger V, Pacchetti C, Pickut B, et al. Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm (2013) 120(11):1553-8. doi:10.1007/s00702-013-1026-9
13. Arai R, Karasawa N, Geffard M, Nagatsu I. l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett (1995) 195(3):195-8. doi:10.1016/0304-3940(95)11817-G
14. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous l-DOPA in the rat, with reference to the involvement of aromatic l-amino acid decarboxylase. Brain Res (1994) 667(2):295-9. doi:10.1016/0006-8993(94)91511-3
15. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain (2007) 130(Pt 7):1819-33. doi:10.1093/brain/awm082
16. Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of l-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse (2009) 63(7):610-20. doi:10.1002/syn.20630
17. Navailles S, Bioulac B, Gross C, De Deurwaerdere P. Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease. Neurobiol Dis (2010) 38(1):136-43. doi:10.1016/j.nbd.2010.01.012
18. Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology (2006) 67(9):1612-7. doi:10.1212/01.wnl.0000242888.30755.5d
19. Nevalainen N, Af Bjerken S, Gerhardt GA, Stromberg I. Serotonergic nerve fibers in l-DOPA-derived dopamine release and dyskinesia. Neuroscience (2013) 260C:73-86. doi:10.1016/j.neuroscience.2013.12.029
20. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport (1999) 10(3):631-4. doi:10.1097/00001756-199902250-00034
21. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology (2001) 57(10):1829-34. doi:10.1212/WNL.57.10.1829
22. Eskow KL, Gupta V, Alam S, Park JY, Bishop C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav (2007) 87(3):306-14. doi:10.1016/j.pbb.2007.05.002
23. Munoz A, Carlsson T, Tronci E, Kirik D, Bjorklund A, Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol (2009) 219(1):298-307. doi:10.1016/j.expneurol.2009.05.033
24. Munoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain (2008) 131(Pt 12):3380-94. doi:10.1093/brain/awn235
25. Bezard E, Munoz A, Tronci E, Pioli EY, Li Q, Porras G, et al. Anti-dyskinetic effect of anpirtoline in animal models of l-DOPA-induced dyskinesia. Neurosci Res (2013) 77(4):242-6. doi:10.1016/j.neures.2013.10.002
26. Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Bjorklund A, et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord (2013) 28(8):1088-96. doi:10.1002/mds.25366
27. Iderberg H, Rylander D, Bimpisidis Z, Cenci MA. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Exp Neurol (2013) 250:116-24. doi:10.1016/j.expneurol.2013.09.003
28. Dupre KB, Eskow KL, Barnum CJ, Bishop C. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology (2008) 55(8):1321-8. doi:10.1016/j.neuropharm.2008.08.031
29. Dupre KB, Ostock CY, Eskow Jaunarajs KL, Button T, Savage LM, Wolf W, et al. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol (2011) 229(2):288-99. doi:10.1016/j.expneurol.2011.02.012
30. Nahimi A, Holtzermann M, Landau AM, Simonsen M, Jakobsen S, Alstrup AK, et al. Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning. J Neurochem (2012) 120(5):806-17. doi:10.1111/j.1471-4159.2011.07598.x
31. Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P, et al. 5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model. Neurobiol Dis (2013) 60:108-14. doi:10.1016/j.nbd.2013.08.014
32. Bishop C, George JA, Buchta W, Goldenberg AA, Mohamed M, Dickinson SO, et al. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur J Neurosci (2012) 36(6):2839-48. doi:10.1111/j.1460-9568.2012.08202.x
33. Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'Isola R, et al. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology (2014) 77:1-8. doi:10.1016/j.neuropharm.2013.09.017
34. Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord (2007) 22(2):179-86. doi:10.1002/mds.21226
35. Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol (2004) 27(2):58-62. doi:10.1097/00002826-200403000-00003
36. Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H, Seyfried CA. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm (2004) 111(2):113-26. doi:10.1007/s00702-003-0094-7
37. Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest (2014) 124(3):1340-9. doi:10.1172/JCI71640
38. Rylander D, Parent M, O'Sullivan SS, Dovero S, Lees AJ, Bezard E, et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol (2010) 68(5):619-28. doi:10.1002/ana.22097
39. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol (1994) 17(1):73-82. doi:10.1097/00002826-199402000-00008